Mukka Proteins FY26 PAT Rises 18.7% to INR 57.1 Cr
Mukka Proteins Limited reported a 18.7% increase in FY26 PAT to INR 57.1 crore, driven by a 44% rise in revenue to INR 1,449.5 crore. Q4 PAT grew 52.6% to INR 21.4 crore. The board approved raising INR 75 crore through NCD issuances and authorized investments in a new Sri Lankan subsidiary and a domestic joint venture for waste management.
*this image is generated using AI for illustrative purposes only.
Mukka Proteins Limited has announced its audited financial results for the quarter and year ended March 31, 2026, reporting strong growth across key metrics. The company achieved a revenue of INR 1,449.5 crore for the full year, a significant increase of 44.0% year-on-year. Profit after tax (PAT) for FY26 stood at INR 57.1 crore, up 18.7% from the previous year, while EBITDA grew 30.9% to INR 145.3 crore. The board approved the financial results at its meeting on May 15, 2026.
Consolidated Performance
Mukka Proteins delivered robust consolidated results for the fourth quarter. Q4 revenue reached INR 380.6 crore, while EBITDA surged 48.0% to INR 49.2 crore. The EBITDA margin expanded by 421 basis points to 12.9%. Q4 PAT rose 52.6% to INR 21.4 crore, with a PAT margin of 5.6%. The company attributed the performance to strong demand, improved pricing, and operational efficiencies.
| Metric | Q4 FY26 | Q4 FY25 | YoY % |
|---|---|---|---|
| Revenue from operations | INR 380.6 crore | INR 381.6 crore | -0.3% |
| EBITDA | INR 49.2 crore | INR 33.2 crore | 48.0% |
| EBITDA Margin | 12.9% | 8.7% | 421bps |
| PAT | INR 21.4 crore | INR 14.0 crore | 52.6% |
| PAT Margin | 5.6% | 3.7% | 194bps |
Fund Raising and Strategic Investments
The board approved raising funds by issuing secured, rated, listed, redeemable non-convertible debentures (NCDs) worth INR 25 crore on a private placement basis via the Electronic Bidding Platform (EBP). Additionally, the board approved raising up to INR 50 crore through NCDs in one or more tranches via EBP or non-EBP. The first tranche of INR 25 crore carries a coupon rate of 12.00% per annum and a tenor of 15 months.
In strategic expansion moves, the board approved incorporating an overseas entity in Sri Lanka, "Lanka Bio Proteins Private Limited", with an investment of up to INR 2.50 crore for a 49% stake. The company also approved an investment of INR 2.55 lakh for a 51% profit-sharing stake in a proposed partnership firm, "MPL FC HRC JV", focused on the treatment and disposal of animal waste.
Strategic Expansion and Sustainability
The company is advancing its sustainable sourcing initiatives through the MarinTrust Improver Programme. To bolster capacity, Mukka Proteins is establishing a new facility in the Aljoubah Industrial Area in Oman, spread over 21,249 sq. mt. The company also secured a contract from BBMP/BSWML for integrated animal waste management in Bengaluru.
Historical Stock Returns for Mukka Proteins
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -3.44% | -5.05% | -9.87% | -16.80% | -30.35% | -48.78% |
How will Mukka Proteins' new Oman facility impact its export revenue mix and overall capacity utilization in FY27?
Could the 49% stake in Lanka Bio Proteins signal further Southeast Asian or South Asian market expansion beyond Sri Lanka?
With NCDs carrying a 12% coupon rate, how might rising debt servicing costs affect PAT margins if EBITDA growth moderates in coming quarters?
15
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
